Bayer Proposes $7.25 Billion Roundup Settlement
Analysis based on 96 articles · First reported Feb 17, 2026 · Last updated Mar 11, 2026
The proposed $7.25 billion settlement by Bayer to resolve Roundup lawsuits is expected to significantly increase its litigation liabilities, but it also offers a path to reduce long-term legal uncertainty. This development led to a notable rise in Bayer's shares, indicating a positive market reaction to the potential resolution of a major legal overhang.
Bayer, the German pharmaceutical and agrochemical giant, has announced a proposed $7.25 billion class action settlement in the United States to resolve thousands of lawsuits alleging its Roundup weedkiller causes non-Hodgkin's lymphoma. This settlement, which needs approval from the United States===St. Louis Circuit Court, aims to cover both current and future claims, with payments stretching over up to 21 years. The agreement does not include an admission of liability or wrongdoing by Bayer. The company's total provisions and liabilities for legal disputes are expected to increase from €7.8 billion to €11.8 billion as a result. This development comes as the United States===Supreme Court of the United States is preparing to hear arguments on Bayer's assertion that the United States===United States Environmental Protection Agency's approval of Roundup without a cancer warning should invalidate claims filed in state courts. Bayer CEO Bill Anderson stated that the settlement provides a 'road to closure' for the company, which has faced years of litigation uncertainty since acquiring Bayer===Monsanto in 2018. The company's shares rose significantly following the announcement, reflecting investor optimism about the potential resolution of this long-standing legal issue.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard